Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1001 and Pembrolizumab in Advanced Melanoma
NCT06697301Phase 3Recruiting
- Sponsor
- Eikon Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2035
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of BDB001 in melanoma, sponsored by Eikon Therapeutics. Started May 2025; status: recruiting.
02
Drugs
BDB001
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06697301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697301.